Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2002 Oct;61(10):863–866. doi: 10.1136/ard.61.10.863

Treating human autoimmune disease by depleting B cells

R Looney 1
PMCID: PMC1753906  PMID: 12228152

Full Text

The Full Text of this article is available as a PDF (113.4 KB).

Figure 1 .

Figure 1

Open in a new tab

Possible effects of rituximab on human autoimmune disease.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arzoo K., Sadeghi S., Liebman H. A. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis. 2002 Oct;61(10):922–924. doi: 10.1136/ard.61.10.922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berentsen S., Tjønnfjord G. E., Brudevold R., Gjertsen B. T., Langholm R., Løkkevik E., Sørbø J. H., Ulvestad E. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol. 2001 Oct;115(1):79–83. doi: 10.1046/j.1365-2141.2001.03078.x. [DOI] [PubMed] [Google Scholar]
  3. Bussel J. B. Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients. Semin Oncol. 2000 Dec;27(6 Suppl 12):91–98. [PubMed] [Google Scholar]
  4. Cartron Guillaume, Dacheux Laurent, Salles Gilles, Solal-Celigny Philippe, Bardos Pierre, Colombat Philippe, Watier Hervé. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002 Feb 1;99(3):754–758. doi: 10.1182/blood.v99.3.754. [DOI] [PubMed] [Google Scholar]
  5. Chan O. T., Hannum L. G., Haberman A. M., Madaio M. P., Shlomchik M. J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med. 1999 May 17;189(10):1639–1648. doi: 10.1084/jem.189.10.1639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chan O. T., Madaio M. P., Shlomchik M. J. B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J Immunol. 1999 Oct 1;163(7):3592–3596. [PubMed] [Google Scholar]
  7. Chan O. T., Madaio M. P., Shlomchik M. J. The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev. 1999 Jun;169:107–121. doi: 10.1111/j.1600-065x.1999.tb01310.x. [DOI] [PubMed] [Google Scholar]
  8. Chan O., Shlomchik M. J. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J Immunol. 1998 Jan 1;160(1):51–59. [PubMed] [Google Scholar]
  9. Clynes R. A., Towers T. L., Presta L. G., Ravetch J. V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000 Apr;6(4):443–446. doi: 10.1038/74704. [DOI] [PubMed] [Google Scholar]
  10. Edwards J. C., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001 Feb;40(2):205–211. doi: 10.1093/rheumatology/40.2.205. [DOI] [PubMed] [Google Scholar]
  11. Gausas J., Paterson P. Y., Day E. D., Dal Canto M. C. Intact B-cell activity is essential for complete expression of experimental allergic encephalomyelitis in Lewis rats. Cell Immunol. 1982 Sep 15;72(2):360–366. doi: 10.1016/0008-8749(82)90484-1. [DOI] [PubMed] [Google Scholar]
  12. Gonzalez-Stawinski G. V., Yu P. B., Love S. D., Parker W., Davis R. D., Jr Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab). Clin Immunol. 2001 Feb;98(2):175–179. doi: 10.1006/clim.2000.4980. [DOI] [PubMed] [Google Scholar]
  13. Hayglass K. T., Naides S. J., Scott C. F., Jr, Benacerraf B., Sy M. S. T cell development in B cell-deficient mice. IV. The role of B cells as antigen-presenting cells in vivo. J Immunol. 1986 Feb 1;136(3):823–829. [PubMed] [Google Scholar]
  14. Janeway C. A., Jr, Ron J., Katz M. E. The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. J Immunol. 1987 Feb 15;138(4):1051–1055. [PubMed] [Google Scholar]
  15. Leandro M. J., Edwards J. C. W., Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002 Oct;61(10):883–888. doi: 10.1136/ard.61.10.883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Levine T. D., Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology. 1999 May 12;52(8):1701–1704. doi: 10.1212/wnl.52.8.1701. [DOI] [PubMed] [Google Scholar]
  17. Li H., Shi F. D., He B., Bakheit M., Wahren B., Berglöf A., Sandstedt K., Link H. Experimental autoimmune myasthenia gravis induction in B cell-deficient mice. Int Immunol. 1998 Sep;10(9):1359–1365. doi: 10.1093/intimm/10.9.1359. [DOI] [PubMed] [Google Scholar]
  18. Liang Y., Buckley T. R., Tu L., Langdon S. D., Tedder T. F. Structural organization of the human MS4A gene cluster on Chromosome 11q12. Immunogenetics. 2001 Jul;53(5):357–368. doi: 10.1007/s002510100339. [DOI] [PubMed] [Google Scholar]
  19. Lin R. H., Mamula M. J., Hardin J. A., Janeway C. A., Jr Induction of autoreactive B cells allows priming of autoreactive T cells. J Exp Med. 1991 Jun 1;173(6):1433–1439. doi: 10.1084/jem.173.6.1433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lyons J. A., San M., Happ M. P., Cross A. H. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol. 1999 Nov;29(11):3432–3439. doi: 10.1002/(SICI)1521-4141(199911)29:11<3432::AID-IMMU3432>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  21. Maloney D. G., Grillo-López A. J., White C. A., Bodkin D., Schilder R. J., Neidhart J. A., Janakiraman N., Foon K. A., Liles T. M., Dallaire B. K. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997 Sep 15;90(6):2188–2195. [PubMed] [Google Scholar]
  22. Mamula M. J., Janeway C. A., Jr Do B cells drive the diversification of immune responses? Immunol Today. 1993 Apr;14(4):151–154. doi: 10.1016/0167-5699(93)90274-O. [DOI] [PubMed] [Google Scholar]
  23. Mamula M. J., Lin R. H., Janeway C. A., Jr, Hardin J. A. Breaking T cell tolerance with foreign and self co-immunogens. A study of autoimmune B and T cell epitopes of cytochrome c. J Immunol. 1992 Aug 1;149(3):789–795. [PubMed] [Google Scholar]
  24. Moulin V., Andris F., Thielemans K., Maliszewski C., Urbain J., Moser M. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med. 2000 Aug 21;192(4):475–482. doi: 10.1084/jem.192.4.475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Myers K. J., Sprent J., Dougherty J. P., Ron Y. Synergy between encephalitogenic T cells and myelin basic protein-specific antibodies in the induction of experimental autoimmune encephalomyelitis. J Neuroimmunol. 1992 Nov;41(1):1–8. doi: 10.1016/0165-5728(92)90188-q. [DOI] [PubMed] [Google Scholar]
  26. Noorchashm H., Noorchashm N., Kern J., Rostami S. Y., Barker C. F., Naji A. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes. 1997 Jun;46(6):941–946. doi: 10.2337/diab.46.6.941. [DOI] [PubMed] [Google Scholar]
  27. Patel K., Berman J., Ferber A., Caro J. Refractory autoimmune thrombocytopenic purpura treatment with Rituximab. Am J Hematol. 2001 May;67(1):59–60. doi: 10.1002/ajh.1081. [DOI] [PubMed] [Google Scholar]
  28. Quartier P., Brethon B., Philippet P., Landman-Parker J., Le Deist F., Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001 Nov 3;358(9292):1511–1513. doi: 10.1016/s0140-6736(01)06573-4. [DOI] [PubMed] [Google Scholar]
  29. Reff M. E., Carner K., Chambers K. S., Chinn P. C., Leonard J. E., Raab R., Newman R. A., Hanna N., Anderson D. R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994 Jan 15;83(2):435–445. [PubMed] [Google Scholar]
  30. Rivera A., Chen C. C., Ron N., Dougherty J. P., Ron Y. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int Immunol. 2001 Dec;13(12):1583–1593. doi: 10.1093/intimm/13.12.1583. [DOI] [PubMed] [Google Scholar]
  31. Ron Y., De Baetselier P., Tzehoval E., Gordon J., Feldman M., Segal S. Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice. II. Anti-mu treatment affects the initiation and recruitment of T cells. Eur J Immunol. 1983 Feb;13(2):167–171. doi: 10.1002/eji.1830130214. [DOI] [PubMed] [Google Scholar]
  32. Ron Y., Sprent J. T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes. J Immunol. 1987 May 1;138(9):2848–2856. [PubMed] [Google Scholar]
  33. Ron Y., de Baetselier P., Gordon J., Feldman M., Segal S. Impairment of antigen-specific T cell proliferative response in B cell suppressed mice. Adv Exp Med Biol. 1982;149:609–615. doi: 10.1007/978-1-4684-9066-4_84. [DOI] [PubMed] [Google Scholar]
  34. Sacchi S., Federico M., Dastoli G., Fiorani C., Vinci G., Clò V., Casolari B. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab. Crit Rev Oncol Hematol. 2001 Jan;37(1):13–25. doi: 10.1016/s1040-8428(00)00069-x. [DOI] [PubMed] [Google Scholar]
  35. Shlomchik M. J., Madaio M. P., Ni D., Trounstein M., Huszar D. The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med. 1994 Oct 1;180(4):1295–1306. doi: 10.1084/jem.180.4.1295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Stasi R., Pagano A., Stipa E., Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001 Aug 15;98(4):952–957. doi: 10.1182/blood.v98.4.952. [DOI] [PubMed] [Google Scholar]
  37. Svensson L., Jirholt J., Holmdahl R., Jansson L. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin Exp Immunol. 1998 Mar;111(3):521–526. doi: 10.1046/j.1365-2249.1998.00529.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Treon S. P., Anderson K. C. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol. 2000 Dec;27(6 Suppl 12):79–85. [PubMed] [Google Scholar]
  39. Willenborg D. O., Prowse S. J. Immunoglobulin-deficient rats fail to develop experimental allergic encephalomyelitis. J Neuroimmunol. 1983 Oct;5(2):99–109. doi: 10.1016/0165-5728(83)90001-2. [DOI] [PubMed] [Google Scholar]
  40. Willenborg D. O., Sjollema P., Danta G. Immunoglobulin deficient rats as donors and recipients of effector cells of allergic encephalomyelitis. J Neuroimmunol. 1986 Apr;11(2):93–103. doi: 10.1016/0165-5728(86)90111-6. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES